QoL during KTd or KRd induction followed by K maintenance or observation
... in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross‐sectional analysis of the randomized AGMT 02 study
Recent publication
In the AGMT02 clinical trial, 20 research centres investigated the effects of two combination therapies on the quality of life of newly diagnosed transplant-ineligible multiple myeloma patients. A total of 123 patients were randomised into two groups. After induction therapy with either KTd or KRd, patients received either maintenance therapy with carfilzomib (K) or observation. Quality of life was assessed using questionnaires, and individual items were compared between therapies and over the course of treatment. Professor Dr Klaus Podar, Head of the Division of Molecular Oncology and Haematology and physician at the Division of Internal Medicine 2 at Krems University Hospital was responsible for data collection at this site. The studywas funded by the Austrian Forum Against Cancer and the results have been published open access in the scientific journal "eJHaem".
Ludwig, H, Melchardt, T, Schweitzer, I, Sormann, S, Schreder, M, Andel, J, Hartmann, B, Zojer, N, Schöffmann, L, Gunsilius, E, Podar, K, Egle, A, Willenbacher, W, Wöll, E, Ruckser, R, Bozic, B, Krauth, M, Petzer, A, Schmitt, C, Machherndl‐spandl, S, Agis, H, Fillitz, M, Wang, S, Knop, S & Greil, R 2024, 'QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross‐sectional analysis of the randomized AGMT 02 study', eJHaem, vol. 5, no. 3, pp. 494-504. https://doi.org/10.1002/jha2.925, https://doi.org/10.1002/jha2.v5.3
